Initial statement of beneficial ownership of securities



>




X0206


3/A


2020-11-18


2020-11-18


0



0001824893


Consonance-HFW Acquisition Corp.


CHFW





0001824774


Consonance Life Sciences




C/O CONSONANCE-HFW ACQUISITION CORP.


1 PALMER SQUARE, SUITE 305


PRINCETON


NJ


08540






1


0


0


0







Class B Ordinary Shares





2210000












D









The shares will automatically convert into Class A Ordinary Shares at the time of the Issuer's initial business combination.


This number includes up to 300,000 shares that are subject to forfeiture in the event the underwriters of the initial public offering of the Issuer's securities do not exercise in full their over-allotment as described in the Issuer's registration statement.


These shares are directly held by Consonance Life Sciences, LLC ("Consonance Life Sciences"). This entity is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston may be deemed to have voting and investment discretion with respect to these shares and may be deemed to have shared beneficial ownership of these shares. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.


This Form 3 amendment is being filed to correct the original Form 3 filed on November 18, 2020. The original Form 3 incorrectly listed the amount of the securities as 2,300,000 Class B Ordinary Shares held by Consonance Life Sciences and incorrectly reported such shares in Table II.



Consonance Life Sciences, LLC ("Consonance Life Sciences") is governed by a board of managers consisting of Mitchell Blutt, Benny Soffer and Kevin Livingston. Dr. Blutt is the Chairman of the Board of Directors (the "Board") of Consonance-HFW Acquisition Corp. (the "Issuer"). By virtue of its representation on the Issuer's Board, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Consonance Life Sciences is deemed a director by deputization of the Issuer.



/s/ Kevin Livingston, Manager of Consonance Life Sciences, LLC


2021-05-19





The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Consonance-HFW Acquisition Corp. makes a similar move, sign up!

Other recent filings from the company include the following:

Kevin Livingston just provided an update on activist position in Consonance-HFW Acquisition Corp. - Sept. 29, 2021

Auto Refresh

Feedback